Dr. Mariana Baz has been an assistant professor at Université Laval since 2022. She also holds the Sentinel North Research Chair in Respiratory Viruses at the Animal-Human Interface: Emergence and Control and a Tier 2 Canada Research Chair in Pre-Pandemic and Pandemic Viruses and Therapeutic Strategies at the same institution. Dr. Baz is Associate Director of the Containment Level 3 (CL3) laboratory at the Infectious Diseases Research Centre (CRCHU Québec-Université Laval). Prior to her current position, Dr. Baz was Senior Scientist and Head of the Antiviral Susceptibility Division at the World Health Organization (WHO) Collaborating Centre for Influenza Reference and Research at the Peter Doherty Institute of Infection and Immunity (University of Melbourne) in Melbourne, Australia.

Dr. Baz trained in Uruguay (BSc in Biochemistry), Canada (MSc and PhD) and the United States (post-doctorate). She is an experienced virologist in pathogenesis, transmission, antiviral therapies and vaccine development/evaluation of seasonal and pandemic respiratory viruses as well as viruses with pandemic potential. Her laboratory focuses on elucidating the molecular mechanisms involved in mammalian respiratory virus adaptation, amplification and disease transmission among animals and from animals to humans as well as new therapeutic strategies against different respiratory viruses, including seasonal and pandemic influenza viruses, highly pathogenic avian influenza viruses, seasonal coronaviruses and SARS-CoV-2, using different in vitro, ex vivo and animal models such as mice, hamsters, guinea pigs and ferrets, representing high-risk populations (immunosuppressed, obese, elderly and others).

Dr. Baz has received several national and international awards including the “Fellows Award for Research Excellence”, NIH and the Vaccine and Edward Jenner Vaccine Society Young Investigator Program. She has published over 60 peer reviewed articles in high impact journals such as NEJM, Lancet ID, J Am Chem Soc, PLoS Path, J Virol, Clin Infect Dis, mBio, J of Virology, Emerg Infect Dis., etc. and is involved in several editorial and review boards for different scientific journals as well as in federal and government agencies in Canada and in Uruguay.

CHUL
2705, boulevard Laurier
R-0709
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 48281 / 48110
mariana.baz@crchudequebec...

Latest news

57 entries « ‹ 1 of 6 › »

Rabezanahary H, Gilbert C, Santerre K, Scarrone M, Gilbert M, Thériault M, Brousseau N, Masson JF, Pelletier JN, Boudreau D, Trottier S, Baz M

Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada

Journal Article

Heliyon, 10 (10), 2024.

Abstract | Links:

Stannard H, Koszalka P, Deshpande N, Desjardins Y, Baz M

Pre-Clinical Evaluation of the Antiviral Activity of Epigalocatechin-3-Gallate, a Component of Green Tea, against Influenza A(H1N1)pdm Viruses

Journal Article

Viruses, 15 (12), 2023.

Abstract | Links:

Panzera Y, Mirazo S, Baz M, Techera C, Grecco S, Cancela F, Fuques E, Condon E, Calleros L, Camilo N, Fregossi A, Vaz I, Pessina P, Deshpande N, Pérez R, Benech A

Detection and genome characterisation of SARS-CoV-2 P.6 lineage in dogs and cats living with Uruguayan COVID-19 patients

Journal Article

Mem Inst Oswaldo Cruz, 117 , 2023.

Abstract | Links:

Silveira F, Rivera-Patron M, Deshpande N, Sienra S, Checa J, Moreno M, Chabalgoity JA, Cibulski SP, Baz M

Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice

Journal Article

Front Immunol, 14 , 2023.

Abstract | Links:

Olivera-Ugarte SM, Bolduc M, Laliberté-Gagné MÈ, Blanchette LJ, Garneau C, Fillion M, Savard P, Dubuc I, Flamand L, Farnòs O, Xu X, Kamen A, Gilbert M, Rabezanahary H, Scarrone M, Couture C, Baz M, Leclerc D

A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection

Journal Article

Nanomedicine, 44 , 2022.

Abstract | Links:

Söderlund-Venermo M, Varma A, Guo D, Gladue DP, Poole E, Pujol FH, Pappu H, Romalde JL, Kramer L, Baz M, Venter M, Moore MD, Nevels MM, Ezzikouri S, Vakharia VN, Wilson WC, Malik YS, Shi Z, Abdel-Moneim AS

World Society for Virology first international conference: Tackling global virus epidemics

Journal Article

Virology, 566 , 2022.

Abstract | Links:

Brown SK, Tseng YY, Aziz A, Baz M, Barr IG

Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors

Journal Article

Antiviral Res, 200 , 2022.

Abstract | Links:

Koszalka P, Subbarao K, Baz M

Preclinical and clinical developments for combination treatment of influenza

Journal Article

PLoS Pathog, 18 (5), 2022.

Abstract | Links:

Longtin Y, Charest H, Quach C, Savard P, Baz M, Boivin G, Farfard J, Villeneuve J, Roger M, De Serres G

Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study

Journal Article

Infect Control Hosp Epidemiol, 43 (1), 2022.

Abstract | Links:

Baz M, Deshpande N, Mackenzie-Kludas C, Mordant F, Anderson D, Subbarao K

SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice

Journal Article

Emerg Infect Dis, 28 (11), 2022.

Abstract | Links:

57 entries « ‹ 1 of 6 › »
Signaler des ajouts ou des modifications

Active projects

  • Aerosol Infection Research: Better mOdels to Reduce iNdoor Exposure (AIRBORNE), from 2022-06-01 to 2025-05-30
  • Canada Research Chair in Pre-pandemic and Pandemic viruses and therapeutic strategies, from 2023-05-01 to 2028-04-29
  • Chaire de recherche Sentinelle Nord sur les virus pandémique et thérapies antivirales, from 2022-04-01 to 2025-03-31
  • Développement de tests sérologiques pour les virus respiratoires et les virus de la variole du singe., from 2023-04-01 to 2026-03-31
  • Plateforme de laboratoire de niveau de confinement 3 pour la recherche sur les virus émergents, from 2023-01-31 to 2025-03-31
  • Prevention of the immunopathology induced by SARS-CoV-2, from 2021-06-01 to 2025-03-31
  • Virus pré-pandémiques et pandémiques et stratégies thérapeutiques, from 2023-04-01 to 2024-12-31

Recently finished projects

  • Fonds de démarrage, Mariana Baz. La grippe à l'interface entre l'homme et l'animal: émergence et contrôle, from 2020-04-13 to 2024-03-31
  • Immunité cellulaire et séroprévalence des anticorps contre SARS-COV-2: Caractérisation de trois populations de travailleurs de l'alimentation, from 2020-11-01 to 2023-09-30
  • Innovative therapeutic approaches for the 2019-novel coronavirus, from 2021-03-01 to 2024-03-31
  • Optimization of a live microneutralization assay to evaluate antibody levels against mpox in vaccinated or infected individuals in Quebec, from 2023-04-24 to 2024-04-23
  • Preclinical proof of concept studies of a new generation of TLR7/8 agonist used in prevention against respiratory viruses and in immunotherapy against lung cancer, from 2023-03-01 to 2024-02-29
  • Understanding the pathogenesis of COVID-19, from 2020-03-01 to 2023-02-28
Data provided by the Université Laval research projects registery